New research identifies potential protective agent against flu
A new study by researchers at the University of Maryland School of Medicine has identified an innovative strategy for treating influenza, and perhaps other infectious diseases as well. Scientists showed that a small protein called retrocyclin-101 (RC-101) could potentially improve the symptoms and mortality associated with the flu and possibly other types of infectious illness as well.
The protein is unique in that it not only targets the flu virus itself, but also the harmful inflammation the virus triggers in the host.
While the effect of RC-101 has been studied as a flu treatment in cells before, it has never been studied in animals. The research appears in the most recent issue of the Journal of Leukocyte Biology.
“Every year, thousands of people across the country die from the flu or its complications — despite widespread use of annual influenza vaccines,” said the study’s lead author, Daniel J. Prantner, a research associate in the Department of Microbiology and Immunology at the University of Maryland School of Medicine (UM SOM). “We think that this protein could lead to medicines that could be a powerful tool in the battle against this disease, and against inflammation in general.”
For this study, Dr. Prantner and his colleagues studied the effects of RC-101 on human cells, and in an animal model of flu, using mice. The researchers studied human immune cells, and found that RC-101 had two positive effects. First, it blocked the flu virus from infecting the cells; second it blocked the runway inflammation that is behind most symptoms of influenza infection, such as fever, pain, lethargy, and trouble breathing. This double action is unique, Dr. Prantner says.
In the animal model, the researchers infected two groups of mice with a dose of influenza that is typically lethal. They gave one of these groups RC-101 two days after infection for a total of five days, and gave the other group a placebo. The mice that were treated with RC-101 exhibited less severe symptoms of the flu and also decreased rates of death. Among the control group, 90 percent of the mice died; among the group that was given RC-101, only 20 percent died.
Although RC-101 does not exist in humans, it does exist in some other animals, including orangutans, and provides powerful antiviral protection. It appears to have been lost over the course of recent primate evolution. Chimpanzees and gorillas, for example, do not have it.
One of the study’s principal investigators, Alfredo Garzino-Demo, PhD, an associate professor in the UM SOM Department of Microbiology and Immunology and at the UM SOM Institute of Human Virology, is planning research to see whether the protein can be effective against Dengue, Zika, and other viral infections that can cause damage via inflammation.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Life-saving vaccine scientist's 100th birthday celebratedon September 7, 2019 at 3:13 am
He would grow up to develop vaccines against measles, mumps, chickenpox, pneumonia, influenza, meningitis and hepatitis and other diseases. Hilleman is credited with saving tens of millions of lives ...
- Transmission of Xofluza-resistant flu virus reported in Japanese siblingson September 6, 2019 at 2:16 pm
A recent report published in Emerging Infectious Diseases detailed a case of likely human-to-human transmission of an influenza A virus with reduced susceptibility to Xofluza between two siblings in ...
- Patterns of seasonal and pandemic influenza-associated health care and mortality in Ontario, Canadaon September 6, 2019 at 7:01 am
Mathematical and statistical models are used to project the future time course of infectious disease epidemics and the expected future burden on health care systems and economies. Influenza is a ...
- Epidemiological and clinical characteristics of children hospitalized due to influenza A and B in the south of Europe, 2010–2016on September 6, 2019 at 2:22 am
Influenza produces annual epidemics that affect 5–15% of the world population. Complications and hospitalizations are more frequent in childhood. This study describes and analyses the epidemiological ...
- Avian Influenza Vaccines Sales Market 2019 Outlook, Opportunity and Demand Analysis Report by 2024on September 5, 2019 at 7:54 am
Sep 05, 2019 (Heraldkeepers) -- New York, September 05, 2019: Market Research Engine has published a new report titled as "Avian Influenza Vaccines Sales Market By Application (Chicken, Duck & ...
- Influenza Diagnostics Market 2019 Global Industry Share, Size Estimation, Demand, Trend, Challenges, Comprehensive Insights, Future Forecasts To 2023on September 4, 2019 at 6:25 pm
The Global Influenza Diagnostics Market is Expected to Register a CAGR of 7.80% to reach USD 954.512 million by 2023. The key players identified in the global influenza diagnostics market are Abbott, ...
- Structures of influenza A virus RNA polymerase offer insight into viral genome replicationon September 4, 2019 at 10:07 am
Fig. 2: Mutations at the interface of the FluPol A dimer inhibit cRNA to vRNA replication. Fig. 3: Structures of H3N2 FluPol A bound to cRNA promoter. Fig. 4: Nb8205, which binds FluPol A at the dimer ...
- Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conferenceon September 3, 2019 at 5:05 am
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50
- Roche's Xofluza reduced risk of contracting influenza in late-stage studyon September 2, 2019 at 5:09 pm
A Phase 3 clinical trial, BLOCKSTONE, evaluating the ability of Roche's (OTCQX:RHHBY) Xofluza (baloxavir marboxil) to prevent a healthy person from contracting influenza from an infected family ...
- Seasonal Influenza Vaccine Market Size Research Report | Growth Forecast 2025on September 2, 2019 at 6:22 am
Sep 02, 2019 (AmericaNewsHour) -- Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, ...
via Bing News